The European Commission has taken a decisive step toward the evolution of the healthcare sector by filing the official proposal for the revision of Regulation (EU) 2017/745 (MDR), already dubbed ‘MDR 2.0’ by industry experts. This initiative stems from the need to address the critical issues that emerged during the initial years of the original regulation’s application, aiming for a system that is not only rigorous in terms of safety but also more streamlined and in sync with modern industrial dynamics.

OBJECTIVES: SUSTAINABILITY AND INNOVATION

The stated objective of the proposal is twofold: to make the regulatory process more predictable and, at the same time, sustainable for manufacturers—particularly small and medium-sized enterprises (SMEs). The current regulatory framework has often acted as a barrier, complicating market access for innovative technologies. With MDR 2.0, Europe aims to support innovation, ensuring that patients have rapid access to cutting-edge medical devices without compromising safety standards.

THE ROLLING REVIEW REVOLUTION

Among the most significant updates is the introduction of the Rolling Review. This approach radically transforms the data submission process: manufacturers will be able to submit sections of their technical documentation as soon as they are completed. Notified Bodies will then have the authority to begin the assessment step-by-step, without having to wait for the full dossier. It is a paradigm shift that promises to significantly streamline certification timelines.

OUTLOOK AND LEGISLATIVE PROCESS

Although the filed text is an official document, it is essential to maintain a cautious perspective: we are still in the proposal stage. The document will now be subject to discussion and may undergo amendments during the legislative process within the European Parliament and the Council. For manufacturers in the sector, now is the time to closely monitor every update to stay prepared for the challenges of an ever-evolving market.